Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0QJDC)

Drug Name
Lixisenatide Drug Info
Synonyms Lyxumia (TN)
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Approved [1]
Cross-matching ID
PubChem CID
90472060
ChEBI ID
CHEBI:85662
CAS Number
CAS 320367-13-3
TTD Drug ID
DM0QJDC
ACDINA Drug ID
D01215

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 2 2.848 3.472 2.963
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-2 diabetes
ICD Disease Classification 5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.